On OX40 and PD-1 combination: Why should OX40 be first in sequence?

Research output: Contribution to journalReview articlepeer-review

Abstract

The larger fraction of patients treated with immune checkpoint inhibitors remain nonresponding eventually. Combination of checkpoint inhibitor and costimulatory antibodies is thought additive, but for such effect, they may require to be given in the right sequence.

Original languageEnglish
Pages (from-to)5999-6001
Number of pages3
JournalClinical Cancer Research
Volume23
Issue number20
DOIs
Publication statusPublished - Oct 15 2017

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'On OX40 and PD-1 combination: Why should OX40 be first in sequence?'. Together they form a unique fingerprint.

Cite this